An outbreak of multidrug-resistant tuberculosis (TB) developed in Kansas in November 2021, and included multiple children who were born in the U.S. and became infected in the state, CDC researchers ...

For patients with multidrug-resistant tuberculosis (TB), taking at least six potentially effective drugs, particularly including pyrazinamide, significantly increased the likelihood of achieving a ...

FRANKLIN LAKES, N.J., April 13, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAXTM Molecular Multi-Drug ...

An estimated 440 000 cases of multidrug-resistant tuberculosis (MDR TB) occurred worldwide in 2008 (3•6% of all TB cases that year), but only 7% of these cases were identified and treated. Extensively ...

Please provide your email address to receive an email when new articles are posted on . Two phase 3 trials showed levofloxacin reduces the risk for multidrug-resistant TB after household exposure.

An international research team headed by scientists at the University of British Columbia has demonstrated how a novel semi-synthetic compound derived from sanguinarine (SG), an alkaloid extracted ...

"Multidrug-resistant TB requires complex management decisions, and additional resources will be required to successfully interrupt transmission and cure patients through timely diagnosis, treatment ...

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is ...

FRANKLIN LAKES, N.J., April 13, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug ...